BioVersys AG (FRA:W33) OCF Margin %: -1,540.02% (As of Dec. 2025)


FRA:W33 BioVersys AG FRA:W33
7 GF Score
Price €28.00
View Full Analysis

What is BioVersys AG OCF Margin %?

BioVersys AG FRA:W33 -0.71% 7 OCF Margin % is -1,540.02% as of Dec. 2025. GuruFocus rates FRA:W33 with a GF Score™ of 7/100. Among 949 Biotechnology companies, BioVersys AG ranks worse than 86.2% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. BioVersys AG's Cash Flow from Operations for the six months ended in Dec. 2025 was €-13.20 Mil. BioVersys AG's Revenue for the six months ended in Dec. 2025 was €0.86 Mil. Therefore, BioVersys AG's OCF Margin % for the quarter that ended in Dec. 2025 was -1,540.02%.

As of today, BioVersys AG's current OCF Yield % is -13.90%.

The historical rank and industry rank for BioVersys AG's OCF Margin % or its related term are showing as below:

FRA:W33' s OCF Margin % Range Over the Past 10 Years
Min: -2743.25   Med: -2743.25   Max: -2743.25
Current: -2738.04

During the past 2 years, the highest OCF Margin % of BioVersys AG was -2743.25%. The lowest was -2743.25%. And the median was -2743.25%.

FRA:W33's OCF Margin % is ranked worse than
86.2% of 949 companies
in the Biotechnology industry
Industry Median: -64.23 vs FRA:W33: -2738.04

BioVersys AG OCF Margin % Related Terms

BioVersys AG OCF Margin % Historical Data

* Premium members only.

The historical data trend for BioVersys AG's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG OCF Margin % Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
OCF Margin %
0.00 -2,744.22

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
OCF Margin % 0.00 0.00 0.00 -1,540.02

FRA:W33 vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, BioVersys AG's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVersys AG OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVersys AG's OCF Margin % distribution charts can be found below:

* The bar in red indicates where BioVersys AG's OCF Margin % falls into.


FRA:W33
7GF Score
BioVersys AG FRA:W33
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

BioVersys AG's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-23.518/0.857
=-2,744.22 %

BioVersys AG's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-13.198/0.857
=-1,540.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -1,540.02% mean?
BioVersys AG (FRA:W33) has a OCF Margin % of -1,540.02% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #818 out of 949 companies in the Biotechnology industry, placing it in the top 86.2%.
Is BioVersys AG's OCF Margin % too high?
BioVersys AG's current OCF Margin % is -1,540.02%. Based on the distribution chart, BioVersys AG ranks #818 out of 949 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioVersys AG has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #818 out of 949 companies for OCF Margin %. This places BioVersys AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BioVersys AG and its competitors. BioVersys AG's current OCF Margin % is -1,540.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (FRA:W33) has a current OCF Margin % of -1,540.02%. The current OCF Margin % is -1,540.02%. BioVersys AG's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For BioVersys AG (FRA:W33), the current OCF Margin % is -1,540.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score

Get the complete analysis for FRA:W33

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.00
Price